A lawsuit filed Tuesday in federal court alleges Merck's Gardasil human papillomavirus (HPV) vaccine caused a young Utah woman to develop cervical cancer and other injuries.

The lawsuit, filed on behalf of Caroline Cantera, 25, by Wisner Baum (formerly Baum Hedlund Aristei & Goldman), is the first lawsuit to allege Gardasil can cause cervical cancer — the very cancer Merck asserts Gardasil prevents.

Cantera alleges New Jersey-based Merck & Co., Inc., and subsidiary Merck Sharp & Dohme oversold Gardasil as a "cervical cancer vaccine" and downplayed known health risks to enhance sales.

Cantera's attorneys filed the complaint in the U.S. District Court for the Western District of North Carolina as part of the Gardasil multidistrict litigation (MDL). Dozens of federal Gardasil injury cases filed throughout the country have been consolidated in North Carolina.

According to the complaint, Merck never studied whether Gardasil prevents cervical cancer. Instead, the drugmaker tested Gardasil to determine if it could prevent the development of certain lesions, some of which are considered related to cancer — even though a majority of such lesions, even the most serious, regress on their own.

Public health officials have long recommended the Pap test as the most effective frontline public health response to prevent cervical cancer. Long before Gardasil was introduced to the market in 2006, cervical cancer rates had been plummeting by up to 80% with the implementation of routine Pap testing.